Why Did HIMS Stock Move Today?

Hims & Hers Health (HIMS) is a telehealth platform offering treatments for sexual health, hair loss, mental health, and weight loss. Its stock is driven by subscriber growth, average order value, the GLP-1 weight loss compounding business, and FDA regulatory decisions on compounded medications.

What causes HIMS to move?

• GLP-1 compounding revenue: Hims & Hers began offering compounded semaglutide (generic Ozempic/Wegovy) at lower prices during the drug shortage period. This became a massive revenue driver - and FDA decisions on compounding eligibility are the biggest HIMS catalyst.
• FDA compounding decisions: The FDA determines whether brand-name GLP-1 drugs are in shortage (allowing compounding) or not. Declarations ending shortage status threaten Hims's GLP-1 business and trigger large stock drops.
• Subscriber growth: Online subscriber count across all categories (sexual health, hair, weight, mental health) signals platform health and multi-product adoption.
• Average order value (AOV): Higher AOV reflects customers adopting multiple treatment categories or premium products - a key ARPU expansion signal.
• Eli Lilly and Novo Nordisk competition: The branded GLP-1 manufacturers (Lilly's Zepbound, Novo's Wegovy) compete directly and have pushed to end the compounding period. Any supply normalization reduces Hims's price advantage.
• Personalized medicine narrative: Hims positions customized compounded GLP-1 formulations as a premium product even post-shortage. Regulatory acceptance of personalized dosing is a key upside catalyst.

Use ExplainThisMove for a real-time explanation of any HIMS move. Also explore: SOFI, AMZN, SPY.